Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 584546, 14 pages
http://dx.doi.org/10.1155/2015/584546
Research Article

Prediction of Drug Indications Based on Chemical Interactions and Chemical Similarities

1Institute of Systems Biology, Shanghai University, Shanghai 200444, China
2Department of Mathematics, Shaoyang University, Shaoyang, Hunan 422000, China
3State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
4Department of Mathematics, East China Normal University, Shanghai 200241, China

Received 9 August 2014; Accepted 11 September 2014

Academic Editor: Tao Huang

Copyright © 2015 Guohua Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. T. Ashburn and K. B. Thor, “Drug repositioning: identifying and developing new uses for existing drugs,” Nature Reviews Drug Discovery, vol. 3, no. 8, pp. 673–683, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. A. L. Hopkins, “Network pharmacology: the next paradigm in drug discovery,” Nature Chemical Biology, vol. 4, no. 11, pp. 682–690, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Usdin, “Industry development: pipeline or flatline?” BioCentury, vol. 1, 2002. View at Google Scholar
  4. C. R. Chong and D. J. Sullivan Jr., “New uses for old drugs,” Nature, vol. 448, no. 7154, pp. 645–646, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. J. T. Dudley, T. Deshpande, and A. J. Butte, “Exploiting drug-disease relationships for computational drug repositioning,” Briefings in Bioinformatics, vol. 12, no. 4, pp. 303–311, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Noeske, B. C. Sasse, H. Stark, C. G. Parsons, T. Weil, and G. Schneider, “Predicting compound selectivity by self-organizing maps: cross-activities of metabotropic glutamate receptor antagonists,” ChemMedChem, vol. 1, no. 10, pp. 1066–1068, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Iorio, R. Bosotti, E. Scacheri et al., “Discovery of drug mode of action and drug repositioning from transcriptional responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 33, pp. 14621–14626, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. J. Keiser, V. Setola, J. J. Irwin et al., “Predicting new molecular targets for known drugs,” Nature, vol. 462, no. 7270, pp. 175–181, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Yamanishi, M. Kotera, M. Kanehisa, and S. Goto, “Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework,” Bioinformatics, vol. 26, no. 12, pp. i246–i254, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Cheng, C. Liu, J. Jiang et al., “Prediction of drug-target interactions and drug repositioning via network-based inference,” PLoS Computational Biology, vol. 8, no. 5, Article ID e1002503, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Gottlieb, G. Y. Stein, E. Ruppin, and R. Sharan, “PREDICT: a method for inferring novel drug indications with application to personalized medicine,” Molecular Systems Biology, vol. 7, article 496, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Re and G. Valentini, “Large scale ranking and repositioning of drugs with respect to DrugBank therapeutic categories,” in Bioinformatics Research and Applications, vol. 7292 of Lecture Notes in Computer Science, pp. 225–236, 2012. View at Publisher · View at Google Scholar
  13. E. Kotelnikova, A. Yuryev, I. Mazo, and N. Daraselia, “Computational approaches for drug repositioning and combination therapy design,” Journal of Bioinformatics and Computational Biology, vol. 8, no. 3, pp. 593–606, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Li, X. Zhu, and J. Y. Chen, “Building disease-specific drug-protein connectivity maps from molecular interaction networks and PubMed abstracts,” PLoS Computational Biology, vol. 5, no. 7, Article ID e1000450, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. P. Chiang and A. J. Butte, “Systematic evaluation of drug-disease relationships to identify leads for novel drug uses,” Clinical Pharmacology and Therapeutics, vol. 86, no. 5, pp. 507–510, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Chen, W.-M. Zeng, Y.-D. Cai, K.-Y. Feng, and K.-C. Chou, “Predicting anatomical therapeutic chemical (ATC) classification of drugs by integrating chemical-chemical interactions and similarities,” PLoS ONE, vol. 7, no. 4, Article ID e35254, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Kanehisa and S. Goto, “KEGG: kyoto encyclopedia of genes and genomes,” Nucleic Acids Research, vol. 28, no. 1, pp. 27–30, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Kuhn, C. von Mering, M. Campillos, L. J. Jensen, and P. Bork, “STITCH: interaction networks of chemicals and proteins,” Nucleic Acids Research, vol. 36, no. 1, pp. D684–D688, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. L. L. Hu, C. Chen, T. Huang, Y. D. Cai, and K. C. Chou, “Predicting biological functions of compounds based on chemical-chemical interactions,” PLoS ONE, vol. 6, no. 12, Article ID e29491, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Dunkel, S. Günther, J. Ahmed, B. Wittig, and R. Preissner, “SuperPred: drug classification and target prediction,” Nucleic Acids Research, vol. 36, pp. W55–59, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. Comprehensive Medicinal Chemistry Database, Accelrys, San Diego, Calif, USA, 2011.
  22. P. Du, T. Li, and X. Wang, “Recent progress in predicting protein sub-subcellular locations,” Expert Review of Proteomics, vol. 8, no. 3, pp. 391–404, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Hu, T. Huang, X. Shi, W.-C. Lu, Y.-D. Cai, and K.-C. Chou, “Predicting functions of proteins in mouse based on weighted protein-protein interaction network and protein hybrid properties,” PLoS ONE, vol. 6, no. 1, Article ID e14556, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. S. C. Gupta, B. Sung, S. Prasad, L. J. Webb, and B. B. Aggarwal, “Cancer drug discovery by repurposing: teaching new tricks to old dogs,” Trends in Pharmacological Sciences, vol. 34, no. 9, pp. 508–517, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. B. M. Padhy and Y. K. Gupta, “Drug repositioning: re-investigating existing drugs for new therapeutic indications,” Journal of Postgraduate Medicine, vol. 57, no. 2, pp. 153–160, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Chen, J. Lu, T. Huang et al., “Finding candidate drugs for hepatitis C based on chemical-chemical and chemical-protein interactions,” PLoS ONE, vol. 9, no. 9, Article ID e107767, 2014. View at Publisher · View at Google Scholar
  27. Y. C. Martin, J. L. Kofron, and L. M. Traphagen, “Do structurally similar molecules have similar biological activity?” Journal of Medicinal Chemistry, vol. 45, no. 19, pp. 4350–4358, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Willett, J. M. Barnard, and G. M. Downs, “Chemical similarity searching,” Journal of Chemical Information and Computer Sciences, vol. 38, no. 6, pp. 983–996, 1998. View at Google Scholar · View at Scopus
  29. C. Steinbeck, C. Hoppe, S. Kuhn, M. Floris, R. Guha, and E. L. Willighagen, “Recent developments of the Chemistry Development Kit (CDK): an open-source Java library for chemo- and bioinformatics,” Current Pharmaceutical Design, vol. 12, no. 17, pp. 2111–2120, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. L. J. Jensen, J. Saric, and P. Bork, “Literature mining for the biologist: from information retrieval to biological discovery,” Nature Reviews Genetics, vol. 7, no. 2, pp. 119–129, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Šarić, L. J. Jensen, R. Ouzounova, I. Rojas, and P. Bork, “Extraction of regulatory gene/protein networks from Medline,” Bioinformatics, vol. 22, no. 6, pp. 645–650, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Weininger, “SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules,” Journal of Chemical Information and Computer Sciences, vol. 28, pp. 31–36, 1988. View at Google Scholar · View at Scopus
  33. N. M. O'Boyle, M. Banck, C. A. James, C. Morley, T. Vandermeersch, and G. R. Hutchison, “Open babel: an open chemical toolbox,” Journal of Cheminformatics, vol. 3, article 33, no. 10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. J. L. Durant, B. A. Leland, D. R. Henry, and J. G. Nourse, “Reoptimization of MDL keys for use in drug discovery,” Journal of Chemical Information and Computer Sciences, vol. 42, no. 6, pp. 1273–1280, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Rogers and M. Hahn, “Extended-connectivity fingerprints,” Journal of Chemical Information and Modeling, vol. 50, no. 5, pp. 742–754, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. S. J. Swamidass, J. Chen, J. Bruand, P. Phung, L. Ralaivola, and P. Baldi, “Kernels for small molecules and the prediction of mutagenicity, toxicity and anti-cancer activity,” Bioinformatics, vol. 21, no. 1, pp. i359–i368, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. RDKit: Open-source cheminformatics, http://www.rdkit.org/.
  38. L. Chen, J. Lu, J. Zhang, K.-R. Feng, M.-Y. Zheng, and Y.-D. Cai, “Predicting chemical toxicity effects based on chemical-chemical interactions,” PLoS ONE, vol. 8, no. 2, Article ID e56517, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. K.-C. Chou and C.-T. Zhang, “Prediction of protein structural classes,” Critical Reviews in Biochemistry and Molecular Biology, vol. 30, no. 4, pp. 275–349, 1995. View at Publisher · View at Google Scholar · View at Scopus
  40. X. Shao, Y. Tian, L. Wu, Y. Wang, L. Jing, and N. Deng, “Predicting DNA- and RNA-binding proteins from sequences with kernel methods,” Journal of Theoretical Biology, vol. 258, no. 2, pp. 289–293, 2009. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  41. D. N. Georgiou, T. E. Karakasidis, J. J. Nieto, and A. Torres, “Use of fuzzy clustering technique and matrices to classify amino acids and its impact to Chou's pseudo amino acid composition,” Journal of Theoretical Biology, vol. 257, no. 1, pp. 17–26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Esmaeili, H. Mohabatkar, and S. Mohsenzadeh, “Using the concept of Chou's pseudo amino acid composition for risk type prediction of human papillomaviruses,” Journal of Theoretical Biology, vol. 263, no. 2, pp. 203–209, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. Y.-S. Ding and T.-L. Zhang, “Using Chou's pseudo amino acid composition to predict subcellular localization of apoptosis proteins: an approach with immune genetic algorithm-based ensemble classifier,” Pattern Recognition Letters, vol. 29, no. 13, pp. 1887–1892, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. C. E. Jones, U. Baumann, and A. L. Brown, “Automated methods of predicting the function of biological sequences using GO and BLAST,” BMC Bioinformatics, vol. 6, article 272, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Chen, W.-M. Zeng, Y.-D. Cai, and T. Huang, “Prediction of metabolic pathway using graph property, chemical functional group and chemical structural set,” Current Bioinformatics, vol. 8, no. 2, pp. 200–207, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Ashburner, C. A. Ball, J. A. Blake et al., “Gene ontology: tool for the unification of biology,” Nature Genetics, vol. 25, no. 1, pp. 25–29, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Chen, B.-Q. Li, and K.-Y. Feng, “Predicting biological functions of protein complexes using graphic and functional features,” Current Bioinformatics, vol. 8, no. 5, pp. 545–551, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Mohabatkar, M. Mohammad Beigi, and A. Esmaeili, “Prediction of GABAA receptor proteins using the concept of Chou's pseudo-amino acid composition and support vector machine,” Journal of Theoretical Biology, vol. 281, no. 1, pp. 18–23, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Chen, J. Lu, N. Zhang, T. Huang, and Y.-D. Cai, “A hybrid method for prediction and repositioning of drug anatomical therapeutic chemical classes,” Molecular BioSystems, vol. 10, no. 4, pp. 868–877, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Kohavi, “A study of cross-validation and bootstrap for accuracy estimation and model selection,” in Proceedings of the 14th international joint conference on Artificial intelligence (IJCAI '95), vol. 2, pp. 1137–1143, San Mateo, Calif, USA, 1995.
  51. B.-Q. Li, K.-Y. Feng, L. Chen, T. Huang, and Y.-D. Cai, “Prediction of protein-protein interaction sites by random forest algorithm with mRMR and IFS,” PLoS ONE, vol. 7, no. 8, Article ID e43927, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Hua and Z. Sun, “Support vector machine approach for protein subcellular localization prediction,” Bioinformatics, vol. 17, no. 8, pp. 721–728, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. K.-J. Park and M. Kanehisa, “Prediction of protein subcellular locations by support vector machines using compositions of amino acids and amino pairs,” Bioinformatics, vol. 19, no. 13, pp. 1656–1663, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Bhasin and G. P. S. Raghava, “SVM based method for predicting HLA-DRB1*0401 binding peptides in an antigen sequence,” Bioinformatics, vol. 20, no. 3, pp. 421–423, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Ben-Hur and W. S. Noble, “Kernel methods for predicting protein-protein interactions,” Bioinformatics, vol. 21, no. 1, pp. i38–i46, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. M. E. Franks, G. R. Macpherson, and W. D. Figg, “Thalidomide,” The Lancet, vol. 363, no. 9423, pp. 1802–1811, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. T. A. Fehniger, J. C. Byrd, G. Marcucci et al., “Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13,” Blood, vol. 113, no. 5, pp. 1002–1005, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Teschner and V. Burst, “Leflunomide: a drug with a potential beyond rheumatology,” Immunotherapy, vol. 2, no. 5, pp. 637–650, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. Y.-J. Ko, E. J. Small, F. Kabbinavar et al., “A multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer,” Clinical Cancer Research, vol. 7, no. 4, pp. 800–805, 2001. View at Google Scholar · View at Scopus
  60. M. R. Knapp and H. K. Beecher, “Postanesthetic nausea, vomiting, and retching; evaluation of the antiemetic drugs dimenhydrinate (dramamine), chlorpromazine, and pentobarbital sodium,” Journal of the American Medical Informatics Association, vol. 160, pp. 376–385, 1956. View at Publisher · View at Google Scholar
  61. R. G. McCreadie, “Managing the first episode of schizophrenia: the role of new therapies,” European Neuropsychopharmacology, vol. 6, supplement 2, pp. S2–S2, 1996. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Hellstrand, E. Eriksson, and C. L. Nilsson, “Dopamine D2 receptor-induced COX-2-mediated production of prostaglandin E2 in D2-transfected Chinese hamster ovary cells without simultaneous administration of a Ca2+-mobilizing agent,” Biochemical Pharmacology, vol. 63, no. 12, pp. 2151–2158, 2002. View at Publisher · View at Google Scholar · View at Scopus
  63. W.-Y. Ong, X.-R. Lu, B. K.-C. Ong, L. A. Horrocks, A. A. Farooqui, and S.-K. Lim, “Quinacrine abolishes increases in cytoplasmic phospholipase A2 mRNA levels in the rat hippocampus after kainate-induced neuronal injury,” Experimental Brain Research, vol. 148, no. 4, pp. 521–524, 2003. View at Google Scholar · View at Scopus
  64. A. Corsini, E. Windler, and M. Farnier, “Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol,” European Journal of Cardiovascular Prevention and Rehabilitation, vol. 16, no. 1, pp. 1–9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Levy and P. S. Jellinger, “The potential role of colesevelam in the management of prediabetes and type 2 diabetes mellitus,” Postgraduate Medicine, vol. 122, no. 3, pp. 1–8, 2010. View at Google Scholar · View at Scopus
  66. B. Staels, “A review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus,” Postgraduate medicine, vol. 121, no. 3, pp. 25–30, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Alvarado, M. M. Mita, S. Vemulapalli, D. Mahalingam, and A. C. Mita, “Clinical activity of mammalian target of rapamycin inhibitors in solid tumors,” Targeted Oncology, vol. 6, no. 2, pp. 69–94, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. C. Récher, O. Beyne-Rauzy, C. Demur et al., “Antileukemic activity of rapamycin in acute myeloid leukemia,” Blood, vol. 105, no. 6, pp. 2527–2534, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. C. Sillaber, M. Mayerhofer, A. Böhm et al., “Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia,” European Journal of Clinical Investigation, vol. 38, no. 1, pp. 43–52, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. G. J. Morgan, F. E. Davies, W. M. Gregory et al., “First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial,” The Lancet, vol. 376, no. 9757, pp. 1989–1999, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Gnant, B. Mlineritsch, W. Schippinger et al., “Endocrine therapy plus zoledronic acid in premenopausal breast cancer,” The New England Journal of Medicine, vol. 360, no. 7, pp. 679–691, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. G. Facchini, M. Caraglia, A. Morabito et al., “Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients. Phase I ZANTE trial,” Cancer Biology and Therapy, vol. 10, no. 6, pp. 543–548, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. P. Workman, P. A. Clarke, F. I. Raynaud, and R. L. M. van Montfort, “Drugging the PI3 kinome: from chemical tools to drugs in the clinic,” Cancer Research, vol. 70, no. 6, pp. 2146–2157, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Jeha, “Tumor lysis syndrome,” Seminars in Hematology, vol. 38, supplement 10, no. 4, pp. 4–8, 2001. View at Publisher · View at Google Scholar
  75. G. B. Elion, “The purine path to chemotherapy,” Science, vol. 244, no. 4900, pp. 41–47, 1989. View at Publisher · View at Google Scholar · View at Scopus